PROGEN — Prostatype Genomics AB Income Statement
0.000.00%
- SEK3.23m
- SEK12.21m
- SEK1.36m
Annual income statement for Prostatype Genomics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 June 30th | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 18 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.074 | 0.684 | 0.01 | 0.683 | 1.36 |
Cost of Revenue | |||||
Gross Profit | 3.31 | 3.92 | 2.51 | 0.683 | 3.73 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.94 | 16.6 | 15.6 | 29.4 | 40.6 |
Operating Profit | -7.86 | -15.9 | -15.5 | -28.7 | -39.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.55 | -17.4 | -15.6 | -29.1 | -41.4 |
Net Income After Taxes | -8.55 | -17.4 | -15.6 | -29.1 | -41.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.55 | -17.4 | -15.6 | -29.1 | -41.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.55 | -17.4 | -15.6 | -29.1 | -41.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.188 | -0.271 | -0.213 | -0.273 | -0.513 |
Dividends per Share |